Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
暂无分享,去创建一个
Christos Hatzis | Lajos Pusztai | Henry Kuerer | G. Hortobagyi | L. Pusztai | S. Singletary | H. Kuerer | W. Symmans | V. Valero | A. Buzdar | C. Hatzis | B. Hennessy | Marjorie C. Green | F. Peintinger | Radhika Rajan | L. Assad | A. Poniecka | W Fraser Symmans | Vicente Valero | Gabriel N Hortobagyi | S Eva Singletary | Radhika Rajan | Anna Poniecka | Marjorie Green | Aman U Buzdar | Bryan Hennessy | Florentia Peintinger | Lina Assad
[1] Anna L. Brown,et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Blohmer,et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Roman Rouzier,et al. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response , 2004, Cancer.
[4] Terry L. Smith,et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Terry L. Smith,et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. , 2000, Journal of the National Cancer Institute.
[6] G. Hortobagyi,et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy , 1988, Cancer.
[7] G. Hortobagyi,et al. Pathological assessment of response to induction chemotherapy in breast cancer. , 1986, Cancer research.
[8] G. Hortobagyi,et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma , 2006, British Journal of Cancer.
[10] Michael W Kattan,et al. Judging new markers by their ability to improve predictive accuracy. , 2003, Journal of the National Cancer Institute.
[11] Donald A. Berry,et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer , 2006 .
[12] P. V. van Diest,et al. Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. , 1997, American journal of clinical pathology.
[13] H. Tsuda,et al. Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer. , 2005, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[14] Jesse A. Berlin,et al. Assessing the Generalizability of Prognostic Information , 1999 .
[15] Frank E. Harrell,et al. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .
[16] D G Altman,et al. What do we mean by validating a prognostic model? , 2000, Statistics in medicine.
[17] G. Bonadonna,et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] G. Hortobagyi,et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M Schumacher,et al. Resampling and cross-validation techniques: a tool to reduce bias caused by model building? , 1997, Statistics in medicine.
[20] Donald L Weaver,et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Andreas Makris,et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] P. Hurteloup,et al. Inflammatory Breast Cancer: Pilot Study of Intensive Induction Chemotherapy (FEC‐HD) Results in a High Histologic Response Rate , 1993 .
[23] Terry L. Smith,et al. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] G. Hortobagyi,et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Thomas R Fleming,et al. Surrogate endpoints and FDA's accelerated approval process. , 2005, Health affairs.
[26] Norman R. Draper,et al. On Distributions and Their Transformation to Normality , 1969 .
[27] A. Hutcheon,et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. , 2003, Breast.
[28] G. Giaccone,et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. , 1998, British Journal of Cancer.
[29] Norman Wolmark,et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] L. Carey,et al. American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. , 2005, Journal of the National Cancer Institute.
[31] G. Hortobagyi,et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Z. Baloch,et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. , 1995, Journal of the American College of Surgeons.
[33] M. Kurosumi. Significance of histopatholoaical evaluation in primary therapy for breast cancer-recent trends in primary modality with pathological complete response(pCR) as endpoint , 2004, Breast cancer.
[34] Richard Simon,et al. Roadmap for developing and validating therapeutically relevant genomic classifiers. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.